PT773785E - Tratamento do cancro utilizando um mutante de hsv - Google Patents

Tratamento do cancro utilizando um mutante de hsv

Info

Publication number: PT773785E
Authority: PT; Portugal
Prior art keywords: mutant; cancer treatment; hsv mutant; gamma; gene
Prior art date: 1994-07-29

Application number

PT95927034T

Other languages

English (en)

Inventor

Alasdair Roderick Maclean

Susanne Moira Brown

Nigel William Fraser

Bruce Paul Randazzo

Original Assignee

Univ Glasgow

Wistar Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-07-29

Filing date

1995-07-28

Publication date

2002-11-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10759079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT773785(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-07-28 Application filed by Univ Glasgow, Wistar Inst filed Critical Univ Glasgow

2002-11-29 Publication of PT773785E publication Critical patent/PT773785E/pt

Links

206010028980 Neoplasm Diseases 0.000 title abstract 2
201000011510 cancer Diseases 0.000 title abstract 2
101150096316 5 gene Proteins 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 1
241000700584 Simplexvirus Species 0.000 abstract 1
241000700605 Viruses Species 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
238000012986 modification Methods 0.000 abstract 1
230000004048 modification Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Mycology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Neurology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)

PT95927034T 1994-07-29 1995-07-28 Tratamento do cancro utilizando um mutante de hsv PT773785E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB9415320A GB9415320D0 (en)	1994-07-29	1994-07-29	Cancer treatment

Publications (1)

Publication Number	Publication Date
PT773785E true PT773785E (pt)	2002-11-29

Family

ID=10759079

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT95927034T PT773785E (pt)	1994-07-29	1995-07-28	Tratamento do cancro utilizando um mutante de hsv

Country Status (12)

Country	Link
US (3)	US7674468B2 (pt)
EP (2)	EP0773785B1 (pt)
JP (2)	JP4321723B2 (pt)
AT (1)	ATE219681T1 (pt)
AU (1)	AU3119995A (pt)
CA (1)	CA2196315C (pt)
DE (1)	DE69527204T2 (pt)
DK (1)	DK0773785T3 (pt)
ES (1)	ES2179880T3 (pt)
GB (1)	GB9415320D0 (pt)
PT (1)	PT773785E (pt)
WO (1)	WO1996003997A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9415320D0 (en) *	1994-07-29	1994-09-21	Medical Res Council	Cancer treatment
ZA966287B (en) *	1995-07-27	1998-03-09	American Cyanamid Co	Avirulent herpetic viruses useful as tumoricidal agents and vaccines.
ATE241994T1 (de) *	1996-01-25	2003-06-15	Univ Glasgow	Hsv-mutant-1716 zur behandlung von mesotheliomen
US5824318A (en) *	1996-07-24	1998-10-20	American Cyanamid Company	Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9615794D0 (en)	1996-07-26	1996-09-04	Medical Res Council	Mutant herpes simplex virus strains and uses thereof
US20030044384A1 (en)	1997-10-09	2003-03-06	Pro-Virus, Inc.	Treatment of neoplasms with viruses
US7470426B1 (en)	1997-10-09	2008-12-30	Wellstat Biologics Corporation	Treatment of neoplasms with viruses
US7780962B2 (en)	1997-10-09	2010-08-24	Wellstat Biologics Corporation	Treatment of neoplasms with RNA viruses
NZ550861A (en)	1999-04-15	2009-03-31	Wellstat Biologics Corp	Treatment of neoplasms with viruses
US6897057B1 (en)	1999-08-31	2005-05-24	The General Hospital Corporation	Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
CA2383372C (en) *	1999-08-31	2010-04-13	The General Hospital Corporation	Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression
DE60041210D1 (de)	1999-09-17	2009-02-05	Wellstat Biologics Corp	Onkolytisches Virus
US8147822B1 (en)	1999-09-17	2012-04-03	Wellstat Biologics Corporation	Oncolytic virus
ES2366608T3 (es)	2001-03-27	2011-10-21	The General Hospital Corporation	Vectores víricos y su uso en métodos terapéuticos.
GB0203285D0 (en)	2002-02-12	2002-03-27	Brown Susanne M	An herpes simplex virus complex
JP2004099584A (ja)	2002-05-02	2004-04-02	Keio Gijuku	Ｈｓｖを用いた抗腫瘍剤
NZ541951A (en)	2003-03-07	2008-03-28	Robarts Res Inst	Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
US7731974B2 (en)	2003-03-27	2010-06-08	Ottawa Hospital Research Institute	Mutant vesicular stomatitis viruses and uses thereof
AU2004223808B2 (en)	2003-03-27	2009-03-26	Ottawa Health Research Institute	Mutant vesicular stomatitis viruses and use thereof
US7897146B2 (en)	2003-11-17	2011-03-01	Crusade Laboratories Limited	Treatment using herpes simplex virus
JP2007511216A (ja)	2003-11-17	2007-05-10	クルセイドラボラトリーズリミテッド	変異ウイルス
CA2600675C (en)	2005-03-07	2015-12-15	Robarts Research Institute	Use of a combination of myxoma virus and rapamycin for therapeutic treatment
CN102026645B (zh)	2006-09-15	2016-01-27	渥太华医院研究机构	溶瘤弹状病毒
RU2751236C2 (ru) *	2016-04-22	2021-07-12	Иммвира Ко., Лимитед	КОНСТРУИРОВАНИЕ ОБЛИГАТНОГО ВЕКТОРА НА ОСНОВЕ ОНКОЛИТИЧЕСКИХ ВИРУСОВ ПРОСТОГО ГЕРПЕСА (oHSV) И КОНСТРУКЦИИ ДЛЯ ТЕРАПИИ РАКА
JP2023540548A (ja) *	2020-09-04	2023-09-25	イノブストーンセラピューティクスリミテッド	抗腫瘍活性を有する化合物及びその使用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4859587A (en)	1984-06-04	1989-08-22	Institut Merieux	Recombinant herpes simplex viruses, vaccines and methods
US5328688A (en)	1990-09-10	1994-07-12	Arch Development Corporation	Recombinant herpes simplex viruses vaccines and methods
CA2051289C (en) *	1990-09-14	2002-11-26	Robert L. Martuza	Viral mediated destruction of neoplastic cells
GB9102126D0 (en) *	1991-01-31	1991-03-13	Smithkline Beecham Biolog	Novel vaccine
ES2183811T3 (es)	1992-03-31	2003-04-01	Arch Dev Corp	Tratamiento de enfermedades tumorigenas con un hsv modificado.
US6139834A (en)	1994-06-23	2000-10-31	Georgetown University	Replication-competent Herpes simplex virus mediates destruction of neplastic cells
US5585096A (en) *	1994-06-23	1996-12-17	Georgetown University	Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5728379A (en)	1994-06-23	1998-03-17	Georgetown University	Tumor- or cell-specific herpes simplex virus replication
GB9415320D0 (en) *	1994-07-29	1994-09-21	Medical Res Council	Cancer treatment
JPH11513390A (ja)	1995-10-06	1999-11-16	アーチデベロップメントコーポレイション	細胞殺傷のウイルス増強のための方法および組成物
ATE241994T1 (de)	1996-01-25	2003-06-15	Univ Glasgow	Hsv-mutant-1716 zur behandlung von mesotheliomen
GB0203285D0 (en)	2002-02-12	2002-03-27	Brown Susanne M	An herpes simplex virus complex
GB0326798D0 (en)	2003-11-17	2003-12-24	Crusade Lab Ltd	Methods for generating mutant virus
WO2007026146A1 (en)	2005-08-30	2007-03-08	Crusade Laboratories Limited	Treatment using herpes simplex virus
JP2007511216A (ja)	2003-11-17	2007-05-10	クルセイドラボラトリーズリミテッド	変異ウイルス
EP2016182B8 (en)	2006-05-11	2015-09-02	Virttu Biologics Limited	Mutant hsv, materials and methods for generation of mutant hsv
US8163292B2 (en)	2007-02-16	2012-04-24	Virttu Biologics Limited	Herpes simplex viruses and methods of viral replication
GB0714578D0 (en)	2007-07-26	2007-09-05	Crusade Lab Ltd	Viruses

1994
- 1994-07-29 GB GB9415320A patent/GB9415320D0/en active Pending
1995
- 1995-07-28 AU AU31199/95A patent/AU3119995A/en not_active Abandoned
- 1995-07-28 JP JP50630496A patent/JP4321723B2/ja not_active Expired - Fee Related
- 1995-07-28 AT AT95927034T patent/ATE219681T1/de active
- 1995-07-28 EP EP95927034A patent/EP0773785B1/en not_active Expired - Lifetime
- 1995-07-28 CA CA2196315A patent/CA2196315C/en not_active Expired - Fee Related
- 1995-07-28 PT PT95927034T patent/PT773785E/pt unknown
- 1995-07-28 ES ES95927034T patent/ES2179880T3/es not_active Expired - Lifetime
- 1995-07-28 DE DE69527204T patent/DE69527204T2/de not_active Expired - Lifetime
- 1995-07-28 WO PCT/GB1995/001791 patent/WO1996003997A2/en not_active Ceased
- 1995-07-28 EP EP01126852A patent/EP1192948A3/en not_active Withdrawn
- 1995-07-28 DK DK95927034T patent/DK0773785T3/da active
2005
- 2005-06-13 US US11/152,591 patent/US7674468B2/en not_active Expired - Fee Related
2007
- 2007-08-06 JP JP2007204520A patent/JP2008037869A/ja active Pending
2010
- 2010-01-22 US US12/692,347 patent/US8067012B2/en not_active Expired - Fee Related
2011
- 2011-11-28 US US13/305,516 patent/US20120141418A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO1996003997A3 (en)	1996-05-02
AU3119995A (en)	1996-03-04
JP4321723B2 (ja)	2009-08-26
US20050260169A1 (en)	2005-11-24
EP0773785B1 (en)	2002-06-26
WO1996003997A2 (en)	1996-02-15
EP1192948A2 (en)	2002-04-03
US7674468B2 (en)	2010-03-09
DE69527204T2 (de)	2003-02-20
US8067012B2 (en)	2011-11-29
DK0773785T3 (da)	2002-10-07
US20120141418A1 (en)	2012-06-07
EP1192948A3 (en)	2002-09-04
CA2196315C (en)	2010-02-09
GB9415320D0 (en)	1994-09-21
JP2008037869A (ja)	2008-02-21
JPH10503766A (ja)	1998-04-07
ES2179880T3 (es)	2003-02-01
EP0773785A2 (en)	1997-05-21
US20100172872A1 (en)	2010-07-08
CA2196315A1 (en)	1996-02-15
DE69527204D1 (de)	2002-08-01
ATE219681T1 (de)	2002-07-15

Publication	Publication Date	Title
DK0773785T3 (da)	2002-10-07	Behandling af cancer ced hjælp af HSV-mutant
AU676349B2 (en)	1997-03-06	Nucleic acid-binding oligomers possessing N-branching for therapy and diagnostics
ATE342724T1 (de)	2006-11-15	Verwendung von herpes-vektoren zur tumortherapie
NO954186L (no)	1995-10-19	Plaster med aktive bestanddeler
ES2190447T3 (es)	2003-08-01	Pañal desechable.
AU3636189A (en)	1990-03-29	Hiv-2 virus variants
TR199701545T1 (xx)	1998-04-21	Yeni dolastatin t�revleri,haz�rlanmalar� ve kullan�mlar�
AU1550797A (en)	1997-08-20	Treatment of non-neuronal cancer using hsv mutant
ES8607020A1 (es)	1986-06-01	Acidos 1-ciclopropilquinolon-3-carboxilicos
AU7161994A (en)	1995-03-23	nucleic acid-binding oligomers possessing C-branching for therapy and diagnostics
ES2187504T3 (es)	2003-06-16	Vectores no oncovirales, basados en el vmmp, con encapsidacion defectuosa.
DE59803648D1 (de)	2002-05-08	Faltbare intraokularlinse
DK0638068T3 (da)	1999-11-22	Fremgangsmåde til fremstilling af (S)-3-amino-1-substitueret-pyrrolidiner
FI98987B (fi)	1997-06-13	Varjoainekoostumus
ATE187722T1 (de)	2000-01-15	Cycloaliphatische acryloyl-monomere
ATE181257T1 (de)	1999-07-15	Testbesteck
FI882444A0 (fi)	1988-05-24	Substituerade vinylkefalosporiner, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
ES2053686T3 (es)	1994-08-01	Nuevos di(met)acrilatos, procedimiento para su fabricacion y su empleo.
BR0012380A (pt)	2002-08-27	2-amino-benzoxazinonas para o tratamento de vìrus do herpes simples
IT1278045B1 (it)	1997-11-17	Uso di 2-amminotetraline-6,7-sostituite per la preparazione di composizioni farmaceutiche atte al trattamento dello shock, e di
DK0459176T3 (da)	1996-01-15	Oligophosphater med antiviral virkning
Yi	1994	Negative effect of nepotism on the development of Korean society and an exploration of an alternative
TR199701011A2 (xx)	1998-04-21	1-karba-(detia)-sefalosforin t�revleri.
ATE119940T1 (de)	1995-04-15	Gewebs-plasminogen-aktivator-derivat.
GR960100092A (el)	1997-11-28	Νεα (2η) φαρμακευτικη χρηση του σκορδου για την παρασκευη οποιασδηποτε μορφης φαρμακου για την θεραπειαν του επιχειλιου ερπητος και του ερπητος των γεννητικων οργανων.